



March 2021  
Drug Monitoring changes—effective May 3, 2021

Dear valued customer,

The following changes are taking place within the Clinical Drug Monitoring offering in order to enhance our medMATCH® reporting, ease of ordering, and ease of prescription entry. These changes will take place May 3, 2021.

A summary of the changes and enhancements are listed below.

### 1. Drug Monitoring ordering enhancements

- Separate order codes will not be needed for drug tests with and without medMATCH
  - There will now be a separate order code for medMATCH, **39158**, which will need to be entered once and will apply to the entire order
- Prescription entry
  - The selection list of prescription drugs will expand to include more medications
  - The number of prescription drugs allowed per patient will increase from 5 to 10 prescriptions
  - Prescription drugs will be entered one time per order

### 2. Drug Monitoring medMATCH report enhancements

- Drug Monitoring medMATCH summary
  - The results summary at the top of the enhanced report will include 3 categories of results, making result interpretation easy:

<b>Prescribed Consistent</b> Drugs prescribed and detected	<b>Prescribed Inconsistent</b> Drugs prescribed but not detected	<b>Not Prescribed Inconsistent</b> Drugs detected but not prescribed
---	---	---

- Prescriptions reported (for medMATCH) with no testing ordered will be listed in the summary to alert the ordering clinician

- Result notes
  - Result notes are listed by drug class to allow for easier interpretation
  - Laboratory developed test (LDT) notes will be consolidated into a single note at the end of the report to reduce multiple messages

- medMATCH interpretation is now available for the following drug tests:

Buprenorphine with Naloxone	Eszopiclone	Mitragynine
Naltrexone	Opioids panel	Zolpidem

### 3. Test discontinuations

The following tests will be discontinued:

- Buprenorphine tests: Drug Monitoring Buprenorphine with reflex and Drug Monitoring Buprenorphine quantitative will be discontinued. Buprenorphine with Naloxone will be available as presumptive with reflex and direct to definitive. The definitive Drug Monitoring Buprenorphine with Naloxone test will include results for both Buprenorphine and Naloxone
- Oxycodone tests: Drug Monitoring Oxycodone quantitative will be discontinued due to low utilization of the Oxycodone definitive only test. Oxycodone is available as presumptive only, presumptive with reflex and is included as a component in the Expanded Opiates quantitative test which reports both Oxycodone and Opiates
- Profile 2 tests: Drug Monitoring Profile 2 screen and Drug Monitoring Profile 2 with reflex will be discontinued due to low utilization. All components are available to be ordered individually

Drug Monitoring test names	Discontinued codes	Discontinued codes (with medMATCH)
Buprenorphine with confirmation	16901	70249
Buprenorphine quantitative	16213	18998
Oxycodone quantitative	16920	70238
Profile 2 screen only (Methadone metabolite, opiates, oxycodone)	92467	NA
Profile 2 with confirmation (Methadone metabolite, opiates, oxycodone)	92461	92453

### 4. New test codes

- medMATCH test code 39158
  - Add this test code, 39158, to orders that will require medMATCH interpretation
  - Use of this code will prompt you to enter the prescription information. You can select up to 10 prescription drugs from our list of medications
- Drug Monitoring crosswalk
  - As a result of the changes, we are retiring the current Drug Monitoring test codes. Please see the enclosed test code crosswalk document for the new codes, or access the document via our website link: <https://www.questdrugmonitoring.com/test-code-directory#>

For non-electronic orders, when an order is placed for a retired code, it will be redirected to the new code. If a retired code with medMATCH is ordered, the order will be redirected to the new code and the medMATCH code will be added. There are some exceptions that will not be automatically redirected, including Buprenorphine with confirmation, Buprenorphine quantitative, Oxycodone quantitative, Profile 2 with confirmation, and Profile 2 screen. If an order is received with the discontinued codes listed in the table above, this will be considered a Test in Question (TIQ). A TIQ report will be generated and sent to you.

Quest Diagnostics continues to improve and enhance our services and offerings. If you have any questions, please contact your sales representative. Thank you for choosing Quest Diagnostics.

Your Quest Drug Monitoring Team